Results 21 to 30 of about 38,526 (184)

Bortezomib alters sour taste sensitivity in mice

Toxicology Reports, 2017
Chemotherapy-induced taste disorder is one of the critical issues in cancer therapy. Bortezomib, a proteasome inhibitor, is a key agent in multiple myeloma therapy, but it induces a taste disorder.
Akihiro Ohishi, Kentaro Nishida, Karin Miyamoto, Mizuka Imai, Ryoko Nakanishi, Kyoko Kobayashi, Akiko Hayashi, Kazuki Nagasawa   +7 more
doaj   +1 more source

Meta‐analysis fails to show any correlation between protein abundance and ubiquitination changes

FEBS Open Bio, EarlyView.
We analyzed over 50 published proteomics datasets to explore the relationship between protein levels and ubiquitination changes across multiple experimental conditions and biological systems. Although ubiquitination is often associated with protein degradation, our analysis shows that changes in ubiquitination do not globally correlate with changes in ...
Nerea Osinalde, Unai Alduntzin, Gorka Prieto, Ugo Mayor   +3 more
wiley   +1 more source

Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis

Blood Cancer Journal
Induction regimens for multiple myeloma (MM) commonly include bortezomib, which has typically been administered twice weekly despite studies demonstrating comparable efficacy and less peripheral neuropathy (PN) with once-weekly bortezomib.
Fieke W. Hoff, Rahul Banerjee, Adeel M. Khan, Georgia McCaughan, Bo Wang, Xiaoliang Wang, James Roose, Larry D. Anderson, Andrew J. Cowan, S. Vincent Rajkumar, Gurbakhash Kaur   +10 more
doaj   +1 more source

A Systematic Review and Meta‐Analysis of the Recurrence of Autoimmune Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune encephalitis (AE) is a disease with a potential for recurrence, and patients receive immunotherapy to prevent it. However, there is no consensus on the duration of immunotherapy. This study aimed to determine the recurrence rate and identify the risk factors for AE to provide guidance on the duration of immunotherapy ...
Shangkai Bai, Sen Zhang, Haipei Zhang, Yating Zhang, Junhong Guo, Xiaoyan Yang   +5 more
wiley   +1 more source

Automating Vascular Biology: An End‐to‐End Automated Workflow for High‐Throughput Blood Vessel‐on‐a‐Chip Production and Multi‐Site Validation

Advanced Healthcare Materials, EarlyView.
AngioPlate384 is a 384‐well open‐top platform that automates production of more than 100 miniaturized, perfusable blood vessels embedded in hydrogel and supported by stromal cells. Stromal‐endothelial co‐culture strengthens blood vessel barrier function and yields responses useful for translational planning. Scalable and automation‐ready, it suits drug
Dawn S. Y. Lin, Hanieh Mohammad Hashemi, Kimia Asadi Jozani, Anushree Chakravarty, Sonya Kouthouridis, Jessica Bonanno, Nicky Anvari, Shravanthi Rajasekar, Feng Zhang, Richard Y. Cheng, Narendra Kumar Singh, Luis Miguel Medina, Marc Durante, Yufang He, Boyang Zhang   +14 more
wiley   +1 more source

TRIM47 Regulates Energy Metabolism via Glycolytic Reprogramming to Drive Hepatocellular Carcinoma Progression and Represents an Efficient Therapeutic Target

Advanced Science, EarlyView.
This study identifies TRIM47 as a key driver of liver cancer progression by promoting glycolysis through ubiquitin‐mediated degradation of the gluconeogenic enzyme FBP1. TRIM47 enhances glucose uptake, lactate and ATP production, and tumor growth and metastasis.
Weijie Sun, Yihang Yuan, Qian Qiu, Kexuan Tan, Xutong Li, Haotian Li, Luyang Kang, Yuting Gu, Ziheng Zhang, Jiayu He, Jiali Li, Junjie Lin, Zihan Xie, Kexing Han, Jiabin Li, Yang Zhang, Ting Wu, Yufeng Gao   +17 more
wiley   +1 more source

Proteasome Inhibitor Bortezomib Suppresses Nuclear Factor-Kappa B Activation and Ameliorates Eye Inflammation in Experimental Autoimmune Uveitis

Mediators of Inflammation, 2015
Bortezomib is a proteasome inhibitor used for hematologic cancer treatment. Since it can suppress NF-κB activation, which is critical for the inflammatory process, bortezomib has been found to possess anti-inflammatory activity.
Sheng-Min Hsu, Chang-Hao Yang, Fang-Hsiu Shen, Shun-Hua Chen, Chia-Jhen Lin, Chi-Chang Shieh   +5 more
doaj   +1 more source

Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.

PLoS ONE, 2010
The proteasome inhibitor bortezomib represents an important advance in the treatment of multiple myeloma (MM). Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the mechanism of ...
Feng Ge, Chuan-Le Xiao, Li-Jun Bi, Sheng-Ce Tao, Sheng Xiong, Xin-Feng Yin, Li-Ping Li, Chun-Hua Lu, Hai-Tao Jia, Qing-Yu He   +9 more
doaj   +1 more source

OTUD6A in Airway Epithelial Cells Exacerbates Allergic Asthma by Promoting Airway Inflammation and Airway Remodeling Through Deubiquitination of hResistin/mRELMα

Advanced Science, EarlyView.
This study elucidates a novel mechanistic role of the deubiquitinase OTUD6A in asthma pathogenesis, uncovering its regulatory function in airway inflammation and airway remodeling through the stabilization of hResistin/mRELMα. This study offers a novel regulatory axis (OTUD6A‐hResistin/mRELMα) in asthma pathogenesis and OTUD6A inhibition as a potential
Weiting Pan, Xinru Xi, Wei Dai, Tingfang Xiao, Yeqing Chen, Xuanyu Chen, Xiangting Ge, Chengguang Zhao, Hui Zhang, Yali Zhang, Weixi Zhang   +10 more
wiley   +1 more source

ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5

JCI Insight, 2022
The proteasome inhibitors (PIs) bortezomib and carfilzomib, which target proteasome 20S subunit beta 5 (PSMB5) in cells, are widely used in multiple myeloma (MM) treatment.
Yan Yang, Yuhan Gao, Jingcao Huang, Zhuang Yang, Hongmei Luo, Fangfang Wang, Juan Xu, Yushan Cui, Hong Ding, Zhimei Lin, Xinyu Zhai, Ying Qu, Li Zhang, Ting Liu, Lingqun Ye, Ting Niu, Yuhuan Zheng   +16 more
doaj   +1 more source